RxDoctor Payments Data

Brandi Baldwin, NP

Family · Hilliard, OHNPI 1619417052

Payments from drug & device makers

$723in general payments, 2019–2025

Across 16 payments — averaging $45.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$157
  • Acadia Pharmaceuticals Inc$144
  • Neurocrine Biosciences, Inc.$134
  • Otsuka America Pharmaceutical, Inc.$122
  • Teva Pharmaceuticals USA, Inc.$111
  • Alpha Cognition USA, Inc.$42
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$61285%
  • Education$11115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$723 in reported general payments places this provider in the 65th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$198,702
Medicare patients
305
Services billed
2,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate14$50,206
Abilify MaintenaAripiprazole15$44,234
SecuadoAsenapine14$12,119
Divalproex Sodium279$9,904
NuedextaDextromethorphan Hbr/Quinidine11$8,610
BelsomraSuvorexant24$8,533
Memantine Hcl151$7,464
Duloxetine Hcl110$5,181
Mirtazapine184$5,064
Lorazepam365$4,816
Lurasidone Hcl39$4,719
Tetrabenazine17$4,006
Trazodone Hcl239$3,698
Olanzapine60$3,547
Ziprasidone Hcl30$3,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$122$44,23415 claims
Avanir Pharmaceuticals, Inc.Nuedexta$157$8,61011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,812 family providers in Ohio.

Other family in Hilliard

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →